Actively Recruiting
SLV-324 Treatment of Metastatic Solid Tumors
Led by Solve Therapeutics · Updated on 2026-02-23
70
Participants Needed
7
Research Sites
100 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-324 across a range of dose levels when administered to subjects with metastatic solid tumors.
CONDITIONS
Official Title
SLV-324 Treatment of Metastatic Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men or women aged 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Histologically or cytologically confirmed diagnosis of solid tumor
- Presence of metastatic disease that progressed during or after prior treatment
- Radiographically measurable disease
- Prior treatment with approved therapies showing survival benefit for the cancer type
- Availability of tumor tissue from fresh biopsy or archival sample
- Availability of recent CT, MRI, or PET/CT scans within 35 days before study drug
- Completion of all previous cancer therapy at least 1 week before study drug start
- Adequate blood, coagulation, liver, and kidney function
- Negative viral tests or adequate treatment for HIV, hepatitis B, and hepatitis C
- For females of childbearing potential, negative pregnancy test and use of contraception until 6 months after final dose
- For males able to father children, use of contraception until 6 months after final dose and no sperm donation until 12 months after final dose
- Willingness and ability to comply with study visits, treatments, tests, and procedures
- Signed informed consent and understanding of study procedures and risks
You will not qualify if you...
- Central nervous system cancer unless brain metastases treated, stable for 4 weeks, and no corticosteroids needed
- Presence of another cancer affecting safety or study results
- Uncontrolled systemic bacterial, fungal, or viral infection at study start
- Significant cardiovascular events or comorbidities
- Abnormalities on screening ECG
- Pregnancy or breastfeeding
- Major surgery within 4 weeks before study drug start
- Use of strong CYP3A4 or CYP1A2 inhibitors or inducers
- Use of drugs that prolong QT interval within 7 days before study drug
- Participation in another therapeutic or imaging clinical trial
- Other conditions that may interfere with study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States, 92663
Actively Recruiting
2
Washington University
St Louis, Missouri, United States, 63110
Actively Recruiting
3
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States, 44106
Actively Recruiting
4
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
Actively Recruiting
5
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
6
Mays Cancer Center; University of Texas Health San Antonio
Houston, Texas, United States, 78229
Actively Recruiting
7
University of Washington / Fred Hutchinson Cancer Center
Seattle, Washington, United States, 98109
Actively Recruiting
Research Team
H
Hong Ren, MD
CONTACT
L
Langdon L Miller, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here